Peptides may be evolving from a specialised drug category into a much broader pharmaceutical manufacturing opportunity.
🔹Applications span diabetes, obesity, oncology, endocrinology and rare diseases
🔹GLP-1 drugs have demonstrated that peptide medicines can address very large patient populations
🔹The next opportunity may lie not only in the drugs, but in the manufacturing ecosystem behind them
👉 A look at the peptide opportunity and India's positioning
September 4, 2026 1K 12
